CHONG KUN DANG PHARMACEUTICAL CORP. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 102,600 KRW | -0.97% |
|
-1.63% | -21.62% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,049,862 | 2,572,971 | 1,312,267 | 1,001,821 | 1,307,442 | - | - |
| Enterprise Value (EV) 2 | 1,057 | 2,484 | 1,343 | 1,066 | 1,059 | 1,010 | 876.4 |
| P/E ratio | 18.6 x | 27.6 x | 31.8 x | 11.5 x | 14.3 x | 12.8 x | 10.8 x |
| Yield | 0.93% | 0.42% | 0.9% | 1.22% | 1.03% | 1% | 1.08% |
| Capitalization / Revenue | 0.97 x | 1.98 x | 0.98 x | 0.68 x | 0.85 x | 0.79 x | 0.75 x |
| EV / Revenue | 0.98 x | 1.91 x | 1.01 x | 0.72 x | 0.69 x | 0.61 x | 0.5 x |
| EV / EBITDA | 11.2 x | 17.1 x | 11.3 x | 7.72 x | 7.09 x | 6.08 x | 4.77 x |
| EV / FCF | 17.4 x | 33.3 x | -40.8 x | 55.1 x | 7.73 x | 7.92 x | 5.49 x |
| FCF Yield | 5.75% | 3% | -2.45% | 1.81% | 12.9% | 12.6% | 18.2% |
| Price to Book | 2.11 x | 4.46 x | 2.24 x | 1.54 x | 1.48 x | 1.34 x | 1.21 x |
| Nbr of stocks (in thousands) | 13,156 | 13,150 | 13,034 | 12,813 | 12,743 | - | - |
| Reference price 3 | 79,802 | 195,659 | 100,680 | 78,190 | 102,600 | 102,600 | 102,600 |
| Announcement Date | 31/01/20 | 08/02/21 | 10/02/22 | 03/02/23 | - | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,079 | 1,301 | 1,334 | 1,472 | 1,541 | 1,645 | 1,736 |
| EBITDA 1 | 94.76 | 145.2 | 119.2 | 138 | 149.3 | 166.1 | 183.8 |
| EBIT 1 | 77.02 | 126.6 | 94.09 | 107.1 | 115 | 131.8 | 151.1 |
| Operating Margin | 7.14% | 9.73% | 7.05% | 7.27% | 7.46% | 8.01% | 8.7% |
| Earnings before Tax (EBT) 1 | 72.73 | 120.1 | 77.36 | 101 | 118.2 | 128.3 | 156.4 |
| Net income 1 | 53.88 | 88.68 | 39.42 | 82.94 | 96.18 | 103.9 | 125 |
| Net margin | 5% | 6.82% | 2.95% | 5.63% | 6.24% | 6.32% | 7.2% |
| EPS 2 | 4,300 | 7,082 | 3,168 | 6,771 | 7,156 | 8,018 | 9,491 |
| Free Cash Flow 3 | 60,720 | 74,601 | -32,942 | 19,336 | 137,000 | 127,512 | 159,667 |
| FCF margin | 5,629.43% | 5,736.1% | -2,469.41% | 1,313.27% | 8,887.74% | 7,752.2% | 9,198.89% |
| FCF Conversion (EBITDA) | 64,079.32% | 51,385.96% | - | 14,007.59% | 91,776.92% | 76,747.98% | 86,885.54% |
| FCF Conversion (Net income) | 112,690.76% | 84,118.95% | - | 23,312.61% | 142,441.26% | 122,755.72% | 127,733.33% |
| Dividend per Share 2 | 740.4 | 822.7 | 907.0 | 952.4 | 1,058 | 1,030 | 1,108 |
| Announcement Date | 31/01/20 | 08/02/21 | 10/02/22 | 03/02/23 | - | - | - |
1KRW in Billions2KRW3KRW in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 341.3 | 355.2 | 338 | 364.8 | 380.7 | 388.9 | 360.1 | 391.8 | 396.2 | 353.4 | 387.8 | 396.5 | 388.3 | 390.8 |
| EBITDA 1 | - | - | - | - | - | - | - | - | - | 33.75 | 42.8 | 43.95 | 28.5 | 40.1 |
| EBIT 1 | 37.02 | 0.9877 | 24.33 | 28.1 | 39.66 | 15.02 | 30.06 | 43.39 | 53.07 | 26.75 | 32.37 | 34.27 | 21.8 | 30.95 |
| Operating Margin | 10.85% | 0.28% | 7.2% | 7.7% | 10.42% | 3.86% | 8.35% | 11.07% | 13.39% | 7.57% | 8.35% | 8.64% | 5.61% | 7.92% |
| Earnings before Tax (EBT) 1 | 24.14 | 0.353 | 23.61 | 26.04 | 37.72 | 13.58 | 30.31 | 43.26 | 52.57 | 31.8 | 29.27 | 33.13 | 21.2 | 28 |
| Net income 1 | 1.273 | -0.9111 | 17.19 | 24.48 | 29.2 | 12.07 | 34.89 | 41.83 | 43.51 | 25.1 | 30 | 31 | 11 | 22 |
| Net margin | 0.37% | -0.26% | 5.08% | 6.71% | 7.67% | 3.1% | 9.69% | 10.68% | 10.98% | 7.1% | 7.74% | 7.82% | 2.83% | 5.63% |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 29/10/21 | 10/02/22 | 29/04/22 | 29/07/22 | 28/10/22 | 03/02/23 | 15/05/23 | 28/07/23 | 27/10/23 | 26/04/24 | - | - | - | - |
1KRW in Billions
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | 6.87 | - | 31.2 | 64.1 | - | - | - |
| Net Cash position 1 | - | 88.5 | - | - | 249 | 297 | 431 |
| Leverage (Debt/EBITDA) | 0.0725 x | - | 0.2618 x | 0.4646 x | - | - | - |
| Free Cash Flow 2 | 60,720 | 74,601 | -32,942 | 19,336 | 137,000 | 127,513 | 159,667 |
| ROE (net income / shareholders' equity) | 11.9% | 17.4% | 7.11% | 14.1% | 11.2% | 11.2% | 12% |
| ROA (Net income/ Total Assets) | 7.29% | 10.4% | 4.06% | 7.85% | 6.88% | 7.18% | 7.8% |
| Assets 1 | 739.4 | 852.2 | 970.4 | 1,057 | 1,398 | 1,448 | 1,603 |
| Book Value Per Share 3 | 37,793 | 43,836 | 44,999 | 50,699 | 69,217 | 76,453 | 84,460 |
| Cash Flow per Share 3 | 6,452 | 8,546 | 1,228 | 5,221 | 10,740 | 11,436 | 13,789 |
| Capex 1 | 20.1 | 32.4 | 48.2 | 44.6 | 38.9 | 39.4 | 39 |
| Capex / Sales | 1.87% | 2.49% | 3.61% | 3.03% | 2.52% | 2.39% | 2.25% |
| Announcement Date | 31/01/20 | 08/02/21 | 10/02/22 | 03/02/23 | - | - | - |
1KRW in Billions2KRW in Million3KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -21.62% | 967M | |
| +18.67% | 43.74B | |
| +23.33% | 22.26B | |
| +16.41% | 14.9B | |
| +9.03% | 13.39B | |
| +40.48% | 12.12B | |
| -8.78% | 6.92B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +13.13% | 5.47B |
- Stock Market
- Equities
- A185750 Stock
- Financials Chong Kun Dang Pharmaceutical Corp.
